Cambridge Nutritional Sciences (LSE:CNSL) ROCE % : -11.27% (As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Cambridge Nutritional Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cambridge Nutritional Sciences's annualized ROCE % for the quarter that ended in Sep. 2023 was -11.27%.

Cambridge Nutritional Sciences ROCE % Historical Data

The historical data trend for Cambridge Nutritional Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambridge Nutritional Sciences ROCE % Chart

Cambridge Nutritional Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-1.31

-42.72

-2.18

-4.54

-24.12

Cambridge Nutritional Sciences Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial															0.19	-9.87	-11.64	-35.86	-11.27

Cambridge Nutritional Sciences ROCE % Calculation

Cambridge Nutritional Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-3.239	/	( ( (17.835 - 3.445)	+	(14.405 - 1.935) )	/ 2 )
	=	-3.239	/	( (14.39	+	12.47)	/ 2 )
	=	-3.239	/	13.43
	=	-24.12 %

Cambridge Nutritional Sciences's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-1.372	/	( ( (14.405 - 1.935)	+	(13.758 - 1.885) )	/ 2 )
	=	-1.372	/	( ( 12.47	+	11.873 )	/ 2 )
	=	-1.372	/	12.1715
	=	-11.27 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Cambridge Nutritional Sciences (LSE:CNSL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cambridge Nutritional Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Cambridge Nutritional Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambridge Nutritional Sciences (LSE:CNSL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cambridge Nutritional Sciences PLC (LSE:CNSL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RVKA:Germany

Address

One Fleet Place, London, GBR, EC4M 7WS

Website

https://www.cnsplc.com

Cambridge Nutritional Sciences PLC is a specialist medical diagnostics company focused on promoting a personalized and functional approach to health and nutrition. The company develops, manufacture and market pioneering diagnostic products associated with food sensitivity and gut health. These products enable healthcare practitioners to make informed decisions that can transform their patients' long-term health.